Idexx Laboratories Inc
IDXX
$569.55
+0.87%
Idexx Laboratories Inc is a leading company in the Medical - Diagnostics & Research industry, focusing on veterinary diagnostics. It is a dominant global provider of diagnostic products, equipment, and software for companion animal and livestock health.
IDXX
Idexx Laboratories Inc
$569.55
Investment Opinion: Should I buy IDXX Today?
Based on a synthesis of the data, the objective assessment is a Hold. The company's outstanding fundamental performance is undeniable, but the stock is in a clear corrective phase following a period of extreme valuation. The current price, while down significantly, still carries a high earnings multiple. Investors should wait for either a more attractive entry point or clearer signs of a technical bottom and sustained earnings growth to justify the premium before considering a new Buy rating.
Sign up to view all
IDXX 12-Month Price Forecast
The conflict between stellar fundamentals and a punishing technical/valuation correction creates a neutral near-term outlook. The path of least resistance appears to be consolidation until growth can outpace multiple contraction.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Idexx Laboratories Inc's 12-month outlook, with a consensus price target around $740.41 and implied upside of +30.0% versus the current price.
Average Target
$740.41
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$456 - $740
Analyst target range
No sufficient analyst coverage available.
Bulls vs Bears: IDXX Investment Factors
IDXX presents a classic growth-at-a-price scenario. The company's fundamentals are strong, with excellent revenue growth, profitability, and cash generation. However, the stock is undergoing a significant technical correction from all-time highs, and its valuation remains elevated, creating near-term headwinds.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 14.3% YoY, indicating robust demand.
- Exceptional Profitability Metrics: ROE of 66.0% and ROA of 25.6% show high capital efficiency.
- Robust Free Cash Flow: $1.05B TTM FCF provides strong liquidity for growth and returns.
- Solid Forward P/E: Forward P/E of 34.2 is lower than trailing, suggesting earnings growth.
Bearish
- Significant Price Downtrend: Stock down 27% from 52-week high, showing sustained selling pressure.
- High Valuation Multiples: Trailing P/E of 51.1 and P/S of 12.6 indicate premium pricing.
- Recent Margin Compression: Net margin declined from 26.5% in Q2 to 24.6% in Q4 2025.
- High Beta and Volatility: Beta of 1.7 suggests stock is 70% more volatile than the market.
IDXX Technical Analysis
The stock has been in a significant downtrend over the observed 180-day period, falling from a high near $767 in late November 2025 to a recent close of $561.89. The price action shows a clear pattern of lower highs and lower lows, indicating sustained selling pressure. Short-term performance has been notably weak. The stock declined 14.44% over the past month and 16.95% over the past three months, significantly underperforming the S&P 500, which fell 5.25% and 4.63% over the same periods, respectively. The current price of $561.89 sits well below the 52-week high of $769.98 but remains significantly above the 52-week low of $356.14. This places the stock approximately 27% off its high, indicating it is in a corrective phase within a longer-term uptrend that began from a much lower base.
Beta
1.72
1.72x market volatility
Max Drawdown
-27.3%
Largest decline past year
52-Week Range
$356-$770
Price range past year
Annual Return
+33.6%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | -10.4% | -3.6% |
| 3m | -15.0% | -4.0% |
| 6m | -9.8% | -2.0% |
| 1y | +33.6% | +16.2% |
| ytd | -15.0% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
Revenue growth remains solid, with Q4 2025 revenue of $1.09 billion representing a 14.28% year-over-year increase. Profitability is strong, with a net margin of 24.62% for the latest quarter, though this is down from the 26.5% net margin seen in Q2 2025, indicating some margin compression sequentially. The company maintains a moderate debt-to-equity ratio of 0.67, suggesting a balanced capital structure. Cash flow generation is robust, with trailing twelve-month free cash flow of $1.05 billion, providing ample liquidity for operations and capital returns. Operational efficiency is exceptional, as evidenced by a very high return on equity (ROE) of 66.0% and a return on assets (ROA) of 25.6%. These metrics indicate the company is highly effective at generating profits from its equity base and assets.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.14%
YoY Comparison
Gross Margin
+0.60%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 51.1, while the forward P/E is 34.2, based on estimated EPS of $26.21. The high trailing multiple reflects the stock's premium pricing relative to current earnings. Peer comparison data is not available in the provided inputs. However, the forward P/E of 34.2 and a Price-to-Sales (P/S) ratio of 12.6 suggest the market is pricing in significant future growth, which is consistent with the company's strong historical execution and high profitability metrics.
PE
51.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 35x~86x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
37.5x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is valuation. With a trailing P/E of 51.1 and a P/S of 12.6, the stock is priced for near-perfect execution of high growth. Any deceleration in revenue growth or further margin compression could lead to substantial multiple contraction, as evidenced by the recent sharp decline. The high beta of 1.696 indicates the stock is highly sensitive to broader market movements, increasing downside risk in a risk-off environment. Furthermore, the lack of a dividend (payout ratio 0%) means total return is entirely dependent on price appreciation, which is currently under pressure. Operational risks appear low given the strong ROE and cash flow, but the company's premium position in veterinary diagnostics makes it susceptible to competitive pressures or regulatory changes.
FAQ
The key risks are valuation compression and high volatility. The stock's high P/E ratio makes it vulnerable to earnings misses or growth slowdowns. Its beta of 1.7 means it typically falls more than the market during downturns. Additional risks include potential margin pressure, as seen in the sequential decline from 26.5% to 24.6%, and a lack of dividend income, making returns fully dependent on volatile price appreciation.
The 12-month outlook is mixed, with a base case for consolidation. Our analysis suggests a 50% probability the stock trades between $560 and $650, a 25% chance it rallies to $700-$770 if growth accelerates, and a 25% chance it falls to $450-$550 on further multiple compression. The average analyst EPS estimate for the forward year is $26.21, which at a forward P/E of 34 implies a price near current levels, supporting a range-bound forecast.
IDXX appears overvalued based on traditional metrics but may be fairly valued for its growth profile. Its trailing P/E of 51.1 is very high, and its P/S ratio of 12.6 is premium. The forward P/E of 34.2 suggests the market expects strong earnings growth. The recent sharp price decline indicates the market is reassessing this premium, moving it from extremely overvalued towards a more reasonable, though still elevated, level.
Currently, IDXX is better classified as a Hold than a new Buy. The company's quality is excellent, with a 66% ROE and 14% revenue growth. However, the stock price is in a pronounced downtrend, down over 27% from its high, and its valuation (P/E of 51) remains rich. Investors should wait for the technical picture to improve or for a more attractive valuation before initiating a position.
IDXX is more suitable for long-term investors who can tolerate volatility. The company's dominant market position, high ROE, and strong cash flow generation are hallmarks of a long-term compounder. However, short-term traders face significant headwinds from the ongoing downtrend and high valuation uncertainty. Patient investors may use periods of weakness to build a position for the long haul.